Successful Treatment With Infliximab in a Patient With Diffuse Subretinal Fibrosis Syndrome - 21/08/11
, Raimon Sanmartí, MD b, Anniken Burés, MD a, Ricardo P. Casaroli-Marano, MD a
Inquiries to Alfredo Adán, MD, Department of Ophthalmology, Hospital Clinic de Barcelona, Calle Villarroel 170, 08036 Barcelona, SpainRésumé |
Purpose |
To report a case of Diffuse Subretinal Fibrosis (DSF) syndrome refractory to immunosuppressive therapy who was successfully treated with anti-tumor necrosis factor-⍺ (TNF)-⍺ monoclonal antibodies infliximab.
Design |
Interventional case report.
Methods |
A 23-year-old male with bilateral choroiditis presented sudden dimness of vision associated to nasal scotoma in his right eye. Complete ophthalmic examination with appropriated clinical and laboratorial evaluations was carried out during all follow-up. Inform consent statement and Internal Ethics Board approval were also obtained for an open-label therapy schedule.
Results |
Extensive temporal subretinal lesion in his right eye and DSF in the left eye were observed. The patient received intravenous infliximab infusion (5 mg/kg) schema. Four weeks after starting treatment his visual acuity improved with decrease in ocular inflammation.
Conclusions |
This report describes a case of DSF syndrome that responded remarkably well to infliximab treatment suggesting that TNF-⍺ could play an important pathogenetic role in this syndrome.
Le texte complet de cet article est disponible en PDF.
Vol 143 - N° 3
P. 533-534 - mars 2007 Retour au numéro
Article précédent
- Prorenin Levels in Retinopathy of Prematurity
- Harumasa Yokota, Taiji Nagaoka, Fumihiko Mori, Taiichi Hikichi, Hiromichi Hosokawa, Hiroshi Tanaka, Yuichi Ishida, Fumiaki Suzuki, Akitoshi Yoshida
- Primary Sclerosing Cholangitis and Uveitis: A Case Series
- Lani T. Hoang, Lyndell L. Lim, R. Christopher Walton, Debra A. Goldstein, Brent Chalmers, James T. Rosenbaum
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?